6 studies on Adipotide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Qingdao Sigma Chemical | 2 | 98.56% | View COA → |
Recent certificates: #11990 (98.281%) · #16656 (99.866%) · #21346 (98.845%)
Manufacturers with published third-party certificates of analysis for Adipotide. Open a vendor to see every batch we've verified.
This research strengthens the understanding of metformin's mechanism of action beyond its primary glucose-lowering effects, highlighting its sustained impact on GLP-1, a key hormone for glucose homeostasis and appetit…
This research is significant because it demonstrates a novel and highly targeted strategy for treating obesity by directly reducing white adipose tissue (WAT). Unlike many existing weight loss drugs that primarily sup…
This commentary highlights a crucial aspect of drug development: accurately identifying the mechanism of action. If adipotide truly reduces fat by inducing apoptosis of blood vessels in white adipose tissue, it repres…
This study highlights a novel therapeutic strategy for metabolic diseases by targeting the adipose tissue vasculature rather than directly reducing fat mass. The ability to improve glucose tolerance and insulin sensit…
This research highlights epigenetic age acceleration as a crucial, early-life biomarker for future cardiovascular disease risk. Identifying adolescents with accelerated biological aging could enable targeted early int…
This study provides compelling evidence that GPER activation with a selective agonist like G-1 can effectively ameliorate key features of obesity and type 2 diabetes in preclinical models. The ability of G-1 to reduce…
Free, no account — handy when you're working with Adipotide.